<html>
<head>
<meta charset="UTF-8"/>
<meta name="tikaGenerated" content="true"/>
<meta name="date" content="2022-05-10T02:20:49Z"/>
<meta name="creator" content="Cichon, Lorraine"/>
<meta name="xmp:CreatorTool" content="Microsoft® Word for Microsoft 365"/>
<meta name="meta:author" content="Cichon, Lorraine"/>
<meta name="meta:creation-date" content="2022-05-10T02:20:49Z"/>
<meta name="created" content="Tue May 10 11:50:49 ACST 2022"/>
<meta name="dc:creator" content="Cichon, Lorraine"/>
<meta name="xmpTPg:NPages" content="15"/>
<meta name="Creation-Date" content="2022-05-10T02:20:49Z"/>
<meta name="dcterms:created" content="2022-05-10T02:20:49Z"/>
<meta name="Last-Modified" content="2022-05-10T02:20:49Z"/>
<meta name="dcterms:modified" content="2022-05-10T02:20:49Z"/>
<meta name="Last-Save-Date" content="2022-05-10T02:20:49Z"/>
<meta name="meta:save-date" content="2022-05-10T02:20:49Z"/>
<meta name="Author" content="Cichon, Lorraine"/>
<meta name="producer" content="Microsoft® Word for Microsoft 365"/>
<meta name="modified" content="2022-05-10T02:20:49Z"/>
<meta name="Content-Type" content="application/pdf"/>
</head>
<body>
<pre>
 
 

  

Clinical Trials 
Submission Guidelines 

Including Clinical Research Groups and 

Investigator Driven Trials   



NORTHERN ADELAIDE LOCAL HEALTH NETWORK 

 

Clinical Trials Submission Guidelines   2 

CONTENTS 
INTRODUCTION ............................................................................................................. 4 

NATIONAL STANDARD OPERATING PROCEDURES FOR CLINICAL TRIALS, INCLUDING 

TELETRIALS IN AUSTRALIA............................................................................................... 5 

SITE SPECIFIC ASSESSMENT   SSA .................................................................................. 5 

TECHNICAL SUPPORT ................................................................................................................ 5 

HELPFUL HINTS ......................................................................................................................... 6 

DUAL SUBMISSION.................................................................................................................... 6 

CLINICAL TRIAL NOTIFICATION   CTN ........................................................................... 7 

CLINICAL TRIALS RESEARCH AGREEMENT   (CTRA) ...................................................... 8 

SCHEDULE 2: ........................................................................................................................ 8 

Governance Fee ........................................................................................................................ 8 

Pharmacy Fee ........................................................................................................................... 9 

PAYEE ...................................................................................................................................... 9 

INDEMNITY..................................................................................................................... 9 

INSURANCE ................................................................................................................. 10 

SA HEALTH EMPLOYEES ........................................................................................................... 10 

DUAL EMPLOYMENT ............................................................................................................... 10 

NON-SA HEALTH EMPLOYEES ................................................................................................... 10 

THIRD PARTY SPONSORS ......................................................................................................... 10 

NALHN Credentialling ............................................................................................................. 10 

ESSENTIAL DOCUMENTS .............................................................................................. 11 

SSA FEE FORM ........................................................................................................................ 11 

STUDY PROTOCOL ................................................................................................................... 11 

PARTICIPANTS INFOMRATION SHEETS CONSENT FORM (PISCF) .................................................. 11 

INVESTIGATORS CVs ................................................................................................................ 11 

GOOD CLINICAL PRACTICE CERTIFICATE .................................................................................... 12 

POLICE CLEARANCES ............................................................................................................... 12 

CONFIDENTIALDY AGREEMENTS FOR NON- SA HEALTH STAFF .................................................... 12 



NORTHERN ADELAIDE LOCAL HEALTH NETWORK 

 

Clinical Trials Submission Guidelines   3 

TRIAL COORDINATOR FORM .................................................................................................... 12 

RADIATION SAFETY REPORT / STANDARD OF CARE DECLARATION BY PI ...................................... 13 

ADVERTISING ......................................................................................................................... 13 

OTHER LEGAL CONTRACTS AND AGREEMENTS ........................................................... 14 

NEXT STEPS................................................................................................................... 15 

SIGNING ................................................................................................................................. 15 

LODGING YOUR APPLICATION .................................................................................................. 15 

  



NORTHERN ADELAIDE LOCAL HEALTH NETWORK 

 

Clinical Trials Submission Guidelines   4 

INTRODUCTION  

 

In accordance with the SA Health Research Governance Directive, all research within the Northern Adelaide 

Local Health Network (NALHN) requires authorisation of the delegated officer (Executive Director of Medical 

Services) before commencing.  The Research Governance Office is keen to discuss your project proposals with 

you at an early stage wherever possible and is here to help navigate the necessary paperwork needed to lodge 

a research application. 

At a minimum, this will include a Site-Specific Assessment (Submitted via GEMS), research protocol, Ethics 

approvals, and other supporting documents, depending on the type of study.   

This guide relates to Clinical Trials, including CRG and Investigator driven trials.  These are trials where NALHN 

is not the Sponsor.  In cases where NALHN is the trial sponsor, please refer to the Investigator Initiated 

Submission Guideline. 

.  




NORTHERN ADELAIDE LOCAL HEALTH NETWORK 

 

Clinical Trials Submission Guidelines   5 

NATIONAL STANDARD OPERATING PROCEDURES FOR CLINICAL TRIALS, INCLUDING 

TELETRIALS IN AUSTRALIA  

Based on the International Council for Harmonisation Guideline for Good clinical practice ICH E6 (R2)   

These National Standard Operating Procedures for Clinical Trials, including Teletrials in Australia have been 
developed to assist organisations engaged in conducting clinical trials in Australia to, wherever possible, standardise 
their procedures for key operations related to clinical trials and specifically teletrials. They have been developed for 
the National Mutual Acceptance (NMA) Scheme in Australia and to support a consistent approach to national 
implementation more broadly. They have been endorsed by all states and territories, together with the Therapeutic 
Goods Administration (TGA) and the National Health and Medical Research Council (NHMRC), through the Clinical 
Trials Project Reference Group (CTPRG).  
The National Standard Operating Procedures for Clinical Trials, including Teletrials, form part of a Teletrials 
Compendium, developed to support a consistent national approach to implementation of teletrials in Australia, 
which includes:  
  the National Principles for Teletrials in Australia, and  

  the National Standard Operating Procedures for Clinical Trials, including Teletrials.  
The documents within the Teletrials Compendium are consistent with minimum standard imposed by the 
International Council for Harmonisation (ICH) Guideline for Good Clinical Practice E6 (R2) - an international ethical 
and scientific quality standard for the design, conduct, performance, monitoring, auditing, recording, analyses and 
reporting of clinical trials that involve participation of humans - and comply with the Integrated Addendum to this 
Guideline published by the TGA. 
 

SITE SPECIFIC ASSESSMENT   SSA 
 

Research that involves a risk of harm is considered more than low risk research.  See link to the  National Statement 
on Ethical Conduct in Human Research (2007 Updated 2018)    
 
Site Specific Assessment Form   Greater than low risk studies are now required to be completed on the Research 
Governance and Ethics Management System (GEMS) website which can be located at, Research GEMS .   Please 
review the user guides for step-by-step instructions on how to navigate the Research GEMS.  

 
GEMS is designed to enable a more consistent and streamlined process for research applicants who wish to conduct 
research within SA Health. 
 
Research GEMS allows researchers to: 

  complete their Human Research Ethics Application and Site-Specific Assessment forms 
  monitor approval progress and 
  submit post approval monitoring to their local Research Office. 

All SA Health sites are now accepting new applications for ethics and site assessments through Research GEMS. All 
Current studies have been migrated into the system and can be accessed through the Research GEMS web-based 
platform. 
 
Feel Free to contact the NALHN Research Secretariat for further guidance or support healthnalhnrgo@sa.gov.au 
 

TECHNICAL SUPPORT  

Please review the user guides for step-by-step instructions on how to navigate the Research GEMS system or contact 

the  NALHN Research Secretariat on phone: 818-29346 or email: healthnalhnrgo@sa.gov.au  for further guidance or 

support.  

 











NORTHERN ADELAIDE LOCAL HEALTH NETWORK 

 

Clinical Trials Submission Guidelines   6 

HELPFUL HINTS 

Frequently Asked Questions regarding GEMS  

Completing the site application part C: Department and Services guide   

 

DUAL SUBMISSION  

Site assessment and ethical review may occur in parallel.  However, the decision to authorise or not authorise 

the commencement of a research project at the site can only be made once the HREC has approved the 

project.  





NORTHERN ADELAIDE LOCAL HEALTH NETWORK 

 

Clinical Trials Submission Guidelines   7 

CLINICAL TRIAL NOTIFICATION   CTN 

 

As detailed on the Therapeutic Goods Administration of Australia (TGA) clinical trials website, the following 

avenues provide for the importation into and/or supply in Australia of 'unapproved' therapeutic goods for use in 

a clinical trial.  

Clinical trials that do not involve 'unapproved' therapeutic goods are not subject to requirements of the CTN or 

CTX schemes. It is the responsibility of the Australian clinical trial sponsor to determine whether a product is 

considered an 'unapproved' therapeutic good 

CTN s are submitted via their online submission portal. Where NALHN is not the CTN sponsor of the clinical trial, 

it is the responsibility of the study sponsor to submit the application and pay the submission fee.  

In some circumstances such as investigator initiated clinical trials, please refer to the Investigator Initiated 

guideline  

In the event NALHN agrees to act as CTN sponsor, any relevant agreements (if any) must be in writing first to 

clarify the obligations NALHN undertakes in its role as sponsor for a particular study and to determine how the 

TGA submission fee will be paid by the group or reimbursed to NALHN (as the case may be).  

NALHN also require researchers to provide all relevant information to be entered into the online CTN form and 

to provide the RGO with a copy of the TGA notification letter as soon as practicab le. The RGO will liaise with you 

regarding management of the CTN process for your study. TGA also charge a fee for lodging a CTN which must 

be paid for by the local research unit out of the Special Purpose Fund (SPF). The NALHN Research Secretariat 

office for Research cannot pay the CTN fee.  

For sponsor initiated clinical trials, please attach a copy of the eCTN to your SSA.  

The online CTN files  Approving Authority Details  for NALHN are as follows:  

For investigator initiated clinical trials, the CTN must be submitted to the Therapeutic Goods Administration by 

the Research Governance Office (please refer to fees schedule for current fees). 

Information on the Clinical Trial Notification/Clinical Trial Exemption schemes is available at 

https://www.tga.gov.au/clinical-trials   

For sponsors submitting eCTNs for clinical trials being conducted at Lyell McEwin or Modbury Hospital the 

approving authority information is provided below: 

Name of Approving Authority:  Northern Adelaide Local Health Network Incorporated operating as Lyell 

McEwin Hospital (select appropriate site), or 

Northern Adelaide Local Health Network Incorporated operating as Modbury Hospital  

Approving Authority Contact Officer:  Lorraine Cichon 

Position:  Research Governance Officer 

Contact Phone:  +61 8 8182 9346 

health.nalhnrgoa.gov.au   







NORTHERN ADELAIDE LOCAL HEALTH NETWORK 

 

Clinical Trials Submission Guidelines   8 

CLINICAL TRIALS RESEARCH AGREEMENT   (CTRA) 

Each clinical trial to be conducted at NALHN and sponsored by a third party must be governed by a written 

agreement clarifying the obligations and responsibilities of the parties involved in the trial. NALHN will only 

accept CTRAs that use the standard agreement templates developed by Medicines Australia.  Please ensure 

that each document has been downloaded from the Medicines Australia website found here. The CTRA should 

be submitted along with the SSA and must be reviewed by the NALHN Research Secretariat Office prior to 

execution being undertaken.  

If your project involves a medicine or device, you need to submit an agreement between the parties involved.  

This is required whether you are involved in a: 

? Collaborative Group project 

? Commercially Sponsored project 

? Contract Research Organisation or, 

? Project funded from a grant 

Medicines Australia Standard CTRA templates  are endorsed by SA Health and should be used wherever possible 

to avoid the need for legal review.   

The Principal Investigator should be named in the Schedule 1. The Principal Investigator may sign the 

agreement, but this is not required  

The Schedule 2 must contain the provision for the payment of Ethics and Governances fees in line with SA 

Health Research Ethics and Governance Review Fees Schedule, with the full budget being supported by the 

divisions Business Consultant where the study is being undertaken.  

Any amendment to the standard agreement must be made using the Special Conditions Schedule via SEBS  

Committee using SEBS Review Template found via this link   please ensure to scroll to the bottom of the page 

to find the SEBS template Schedule 7 or  Schdule 4 varaiation to the CTRA Template.  

Site details for inclusion in the template (select appropriate site):  

Name of Institution: Northern Adelaide Local Health Network Incorporated, operating as Lyell 

McEwin Hospital 

Address: Haydown Road, Elizabeth Vale, South Australia 5112 

ABN: 46 371 200 573 

Name of Institution: Northern Adelaide Local Health Network Incorporated, operating as Modbury 

Hospital 

Address: 41-69 Smart Road, Modbury, South Australia 5092 

ABN: 46 371 200 573 

 

SCHEDULE 2:  

Governance Fee 

Research governance submission fees are payable to the Institution according to the current fee schedule. The 

research governance office will invoice the sponsor directly.  

 

  







NORTHERN ADELAIDE LOCAL HEALTH NETWORK 

 

Clinical Trials Submission Guidelines   9 

Pharmacy Fee 

Be aware that SA Health may require a separate pharmacy agreement. Please contact 

Health.LMHClinicalTrialsPharmacy@sa.gov.au  

PAYEE 

All payments listed in this schedule will be made by the Sponsor to Institution upon receipt of a tax invoice by 

direct credit. 

The NALHN banking details are: -  

Bank: Commonwealth Bank of Australia 
Branch: 96 King William St, Adelaide 
BSB: 065 266      Account Number: 10020646 
Account Name: NALHN Oracle Operating 
ABN: 46 371 200 573 
Swift Code: CTBAAU2S 
 

Note: The sponsor is responsible for study payments and must be the party in Schedule 2 that NALHN will 

invoice. 

For information on how to negotiate the study budget for inclusion in the CTRA please review th e Budget 

negotiation NALHN research projects   

INDEMNITY  

Medicines Australia Standard Indemnity templates are endorsed by SA Health. 

Site details for inclusion in the template (select appropriate site):  

Northern Adelaide Local Health Network Incorporated, operating as Lyell McEwin Hospital 

 ( the Indemnified Party ) 

or 

Northern Adelaide Local Health Network Incorporated, operating as Modbury Hospital  

 ( the Indemnified Party ) 

  







NORTHERN ADELAIDE LOCAL HEALTH NETWORK 

 

Clinical Trials Submission Guidelines   10 

INSURANCE  

The Principal Investigator (PI) is responsible for confirming the insurance and indemnity arrangement for the 

research project. The PI must provide all required supporting documentation to the RGO. This generally includes 

copies of the relevant insurance certificates PLUS an email from the partnering organisation confirming that this 

study is covered by the insurance.  

Any changes to insurance (including annual renewal) must be lodged with the RGO for ratification.  

Please be aware that some projects will require Legal Governance and Insurance Services (LGIS) to review and 

approve insurance, and this can delay the processing of your SSA. 

SA HEALTH EMPLOYEES   

SA Health employees conducting a research project in the capacity of their employment with SA Health are 

covered by SA Health insurance where approval from a SA Health HREC or National Mutual Acceptance (NMA) 

HREC has been obtained.  No further supporting documentation is required.  

DUAL EMPLOYMENT  

If the researcher is an SA Health Employee, but has dual employment with a University or South Australian 

Health and Medical Research Institute (SAHMRI) or another organisation, or is also a university student, and is 

conducting a research trial/project in the capacity of their non SA Health employment, or as pa rt of their 

private studies, indemnity must be provided by the University or SAHMRI and/or third party sponsor.  

NON-SA HEALTH EMPLOYEES 

Conducting research at an SA Health organisation that involve SA Health patients, staff, resources or data to 

support the project, the PI must provide appropriate insurance documentation from the non-SA Health 

organisation. Appropriate insurance documentation includes current insurance certificate/s and written 

insurance approval from the organisation. These requirements include research projects conducted by staff 

and students of academic institutions, such as Universities 

THIRD PARTY SPONSORS 

For clinical research TRIALS with third party sponsors it is a requirement that the Sponsor indemnifies the trial 

and provides evidence of indemnity, by way of Certificate of Currency (this is in addition to SA Health and/or 

non-SA Health insurance cover).  

For research PROJECTS sponsored by a third party, including commercially sponsored clinical trials, the sponsor 

must supply evidence of its insurance cover. A sponsor s insurance cover must as a minimum identify the local 

site, investigator and research staff, and participants involved in the research project. For all commercially 

sponsored clinical trials, the  Medicines Australia Form of Indemnity for Clinical Trials   Standard  must also be 

submitted. 

NALHN Credentialling  

NALHN must ensure all staff, contractors, visiting private practit ioners, volunteers and students are 

credentialed. If any of the investigators listed on the application are working at NALHN in clinical capacity, they 

must have up-to-date credentialing within NALHN. If the credentialing details are out of date, we will request 

evidence of renewal and the study will not proceed.  

NALHN Credentialling Officer-  Telephone 08 82821699 or email   

Megan Glowik health.nalhncredentialling@sa.gov.au 




NORTHERN ADELAIDE LOCAL HEALTH NETWORK 

 

Clinical Trials Submission Guidelines   11 

ESSENTIAL DOCUMENTS  

 

SSA FEE FORM  

 

The NALHN Office for Research charges fees according to the SA Health Research Ethics and Governance Fees 

Schedule available here. Please see the SA Health Fee Form  SA Health Research Governance Fee Schedule  

Within the SA Health fees schedule there are three categories that are covered:  

1. Clinical Trials with Full Commercial Sponsorship  

2. Non-Commercially Sponsored Clinical Trials / Cooperative Research Group (CRG) 

3. Contract Review To define clinical trials we acknowledge the following the World Health Organisation 

definition:  

A clinical trial is any research study that prospectively assigns human participants or groups of humans to one or 

more health-related interventions to evaluate the effects on health outcomes 

HUMAN RESEARCH ETHICS COMMITTEE (HREC) 

NALHN does not have a Human Research Ethics Committee; however, the Research Governance Office will accept 

any National Mutual Accepted HREC ethics with a Site-Specific Assessment form. NMA Ethics committees can be 

located on the SA Health website. 

STUDY PROTOCOL  

The Study Protocol is an essential document for both the HREC and the RGO.  

INVESTIGATOR BROCHURE 

Where the trial involves drugs and/or devices, the Trial Sponsor will provide the Investigator Brochure.  Where 

devices are approved for use in Australia or internationally, an Instruction for Use (IFU) document could be 

submitted as a replacement for the investigator brochure. 

The title, version and date listed on the Investigator Brochure should be listed in the research protocol and 

must match those listed on the HREC approval letter (including all future variations).  

Please ensure that the filename is  IB_Version_Date   

PARTICIPANTS INFOMRATION SHEETS CONSENT FORM (PISCF)  

NALHN endorses use of the NHMRC standardised PICFs which are designed for three categories of participants 

identified by the National Statement:  

When completing the Master PISCF and Site Specific PISCF please refer to the Participant Information Sheets 

and Consent Forms fact sheet. 

INVESTIGATORS CVs 

All study Investigators should provide a current copy of their Professional/Academic CV.  Please ensure that the 

CV details relevant research experience, academic qualifications and publications  











NORTHERN ADELAIDE LOCAL HEALTH NETWORK 

 

Clinical Trials Submission Guidelines   12 

GOOD CLINICAL PRACTICE CERTIFICATE 

As part of the implementation of the National Clinical Trials Governance Framework and the Therapeutic Goods 

Administration (TGA) GCP Inspection Audits, investigators will be required to undertake GCP training and 

subsequent refresher training to meet compliance as mandated by SA Health.  

The various Health Networks are working with SA Health towards ensuring that all staff involved in  any clinical 

research (not only those involved in the design and conduct of clinical trials) undertake GCP training and hold a 

current certificate in GCP. This includes principal investigators, associate investigators, trial 

managers/coordinators and research nurses etc. 

To ensure NALHN is compliant with the minimum training requirements, all staff (NALHN, SAHMRI, University 

etc) involved with undertaking any clinical research at NALHN must undertake GCP training. Evidence of GCP 

training will be part of the research ethics and research governance approval processes. 

Certificates are kept on file in the Research Governance Office, so if you have provided a certificate within the 

past two years, you do not need to provide it with every new SSA application.  

Further information can be found on the Therapeutic Goods Administration website.  

  Global Health Network Training Centre 

  Syneos Health (formerly INC Research) 

Please note: This is interim advice and further information will be provided when available from SA Health  

POLICE CLEARANCES  

Non-SA Health staff coming on site as part of a research study must provide a NALHN confidentiality deed and 

National Police Certificate (NPC) if they are working with adults at NALHN.  If the study involves participants 

under the age of 18, child-related employment screening through the Department of Human Services (DHS) must 

be provided in place of an NPC. This is to be in compliant with the South Australian Health Criminal and Relevant 

History Screening Policy Directive available Criminal and Relevant History Screening. There are numerous options 

for a police check online via accredited agencies. As a way to ensure compliance, screening and confidentiality 

are standard conditions on our governance authorisation:  

It is the responsibility of the Principal Investigator to ensure any non-SA Health personnel who conducts or 

monitors research meets SA Health screening requirements as per the SA Health Criminal &amp; Relevant Hist ory 

Screening Policy Directive before they access any SA Health site. The cost of any such screening is the 

responsibility of the individual accessing the site or their employer. Working with children check  

CONFIDENTIALDY AGREEMENTS FOR NON- SA HEALTH STAFF  

A Confidentiality deed for non- NALHN employee will need to be signed by all non-SA Health staff that will require 

access to SA Health data. 

TRIAL COORDINATOR FORM  

NALHN rgo Research Coordinator Authorisation Form | SA Health 

  










NORTHERN ADELAIDE LOCAL HEALTH NETWORK 

 

Clinical Trials Submission Guidelines   13 

RADIATION SAFETY REPORT / STANDARD OF CARE DECLARATION BY PI  

Standard of Care Radiation Letter Template 

Research involving gene technology and related therapies,  drugs and/or ionising radiation may require specific 

notification, registration or licence requirements. Please refer to the SA Health Research Ethics Operational 

Policy Directive. 

All research involving any form of radiation must comply with relevant Nat ional and State legislation, 

organisational policies and procedures, and codes and standards of practice provided by the NHMRC and the 

Australian Radiation Protection and Nuclear Safety Agency (ARPANSA).  

Evidence of these requirements (including the HREC approval) should be attached to the SSA to permit the RGO 

to assess whether the appropriate processes and documents have been completed by the applicant.  

 

ADVERTISING  

All advertisements including the SA Health Logo, and all radio/television/press/social me dia advertising must be 

first approved by the NALHN Communications Department: 

HEALTH.NorthernCommunication@sa.gov.au 

Evidence of approval from Media and Communications must be included with your SSA/LNR.  

Corporate Identity Policy  

https://www.sahealth.sa.gov.au/wps/wcm/connect/ddbe6580462bc31e8967896dc301fde5/Directive_Corporat

e%2BIdentity_Nov2014.pdf?MOD=AJPERES&amp;CACHE=NONE&amp;CONTENTCACHE=NONE 

 Social Media Policy 

https://www.sahealth.sa.gov.au/wps/wcm/connect/public+content/sa+health+internet/contact+us/social+med

ia+policy+terms+and+conditions+of+use 

 

SA Health Logos  

                             

 

 

 

 

             









NORTHERN ADELAIDE LOCAL HEALTH NETWORK 

 

Clinical Trials Submission Guidelines   14 

OTHER LEGAL CONTRACTS AND AGREEMENTS  

The NALHN Executive Director of Medical Services / or nominated delegate is the only person authorised to 

sign contracts on behalf of NALHN. Do not edit the body of the standard agreement. Any non -standard 

agreements (not on an approved template) will need to be reviewed by a legal representative prior to signing.  

It is essential that any third-party agreements be negotiated and presented for signing at the same time as the 
researcher lodges the SSA.   

These commonly include: 

 

  Collaboration agreements with Universities/Medical Research Institutes/Hospitals 

  Funding agreements 

  Material Transfer Agreements (MTAs) 

  Multi-Institution Agreements (MIAs) 

  Intellectual Property Deeds 

  Moral Rights declarations 

  Service agreements 

  Import/Export permits 

  Student scholarship agreements 

  Sanctioned Country clearances 

Researchers should be aware that contract negotiations may take months, so these should be discussed with  
the Research Secretariat at the earliest opportunity. 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 



NORTHERN ADELAIDE LOCAL HEALTH NETWORK 

 

Clinical Trials Submission Guidelines   15 

NEXT STEPS  

 

SIGNING  

  Frequently Asked Questions regarding GEMS  

  Completing the site application part C: Department and Services guide  

 

LODGING YOUR APPLICATION 

For all Greater than Low Risk (SSA)   Follow the GEMS system process as listed above.  

Hard copies are not required (except for CTRA and Medicines Australia Indemnity forms) 

Note that if your submission is being managed via GEMs you will need to ensure that the CTRA and Medicines 

Australia Indemnity forms are provided to the Research secretariat via email healthnalhnrgo@sa.gov.au  

NOTE CONTRACTS are not managed via GEMS.  You need to email these to us. healthnalhnrgo@sa.gov.au  

Once submitted, your application is reviewed by the RGO for final authorisation by the CEO/delegate.  The project 

must not commence until you receive a letter of authorisation from the RGO. 

NALHN supports dual submission of ethics and governance.  While SSAs can be submitted at any time before the 

project commences, dual submission allows the governance and ethical review to occur in parallel.  Your HREC 

approval is not sufficient to start the study. A final endorsement letter will be provided for the SSA only where 

HREC approval is obtained and the letter provided to the RGO. 

Partially completed (unsigned/invalid) applications will be returned Via the GEMS system as ineligible for you to 

correct or provide the required corrections and then resubmit via GEMS.   

Please contact the RGO if you anticipate a lengthy delay in submitting an SSA. 

Contact Us  

The team at the Research Secretariat are happy to assist you in navigating the necessary documents and 

processes outlined in this guide, and to give advice on project-specific information.   

Contact us on +61 8 8182 9346 or healthNALHNrgo@sa.gov.au 

 

 

For more information 
NALHN Research Secretariat 

Lyell McEwin Hospital  

Level 2 Clinical Trials Unit  

Haydown Road 

ELIZABETH VALE SA  5112 

(08) 8182 9346 

email:  healthNALHNRGO@sa.gov.au 

sahealth.sa.gov.au/nalhn 








</pre>
</body>
</html>